FOLFOX Plus Panitumumab vs FOLFOX Alone as Additive Therapy Following R0/1 Resection of RAS Wild-Type Colorectal Cancer Liver Metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314)
Eur. J. Cancer 2022 Sep 01;173(xx)297-306, DP Modest, M Karthaus, S Kasper, N Moosmann, V Keitel, A Kiani, J Uhlig, L Jacobasch, L Fischer V Weikersthal, M Fuchs, F Kaiser, C Lerchenmüller, D Sent, C Junghanß, S Held, S Lorenzen, K Kaczirek, A Jung, S Stintzing, V HeinemannFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.